688192 Dizal
- 36.90
- -0.49-1.31%
Dizal News
Public Companies Are Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Biggest Owners and Were Hit After Market Cap Dropped CN¥2.3b
Gao Ruizhe's rapid listing in two days landed for the first time, and "Dizhe speed" first benefited Chinese patients.
Shanghai, June 27th, 2024 / PRNewswire / -- Dezera Pharmaceutical (stock code: 688192.SH) has become the first and only company in the world to be approved for its high-selectivity JAK1 inhibitor Gushizeti, which is used to treat lymphoma. Two days after obtaining the Drug Registration Certificate from the National Medical Products Administration (NMPA), Gushizeti has been officially available in hospitals and pharmacies nationwide, and the first prescriptions have been issued across the country. Dr. Zhang Xiaolin, founder, director and CEO of Dezera Pharmaceutical, said: "I am very proud to have achieved the rapid listing of Gushizeti in China within two days, far exceeding the fastest speed of my peers."
Dizal Pharmaceutical Gets Nod to Market Golixitinib Capsules
Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
A global first! DiZhe Pharmaceutical's Gaudrela has been approved for listing in China, breaking the "10-year global no innovative drugs" impasse for peripheral T-cell lymphoma.
Relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) has high malignancy, strong heterogeneity, complex pathogenesis, poor prognosis, and a 3-year survival rate of only 23%. There have been no innovative drugs for r/r PTCL in the past decade, and the efficacy of monotherapy is currently limited, urgently needing breakthroughs in new treatment regimens with significant therapeutic effects. Gerocea is the world's first and only new mechanism treatment drug for PTCL that targets the JAK/STAT pathway. Gerocea monotherapy for PTCL breaks through the treatment bottleneck: achieving deep remission, overall benefit, and longer survival. Shanghai, June 19, 2024 / PRNewswire/
Dizhe Pharmaceutical (688192.SH): Gao Ruizhe (Golixetinib capsules) received approval from the National Medical Products Administration (NMPA) to enter the market.
On June 19th, Gelunhui reported that DiZhe Pharmaceutical (688192.SH) announced that its self-developed Class I new drug Gao Ruizhe (generic name: Gori Xi Ti Ni capsule) has officially been approved by the National Medical Products Administration (NMPA) and is applicable to adult patients with relapsed or refractory peripheral T-cell lymphoma (r/rPTCL) who have received at least first-line systemic treatment. Gao Ruizhe is the world's first and only new drug that acts on the JAK/STAT pathway to treat peripheral T-cell lymphoma. Monotherapy has shown breakthrough advantages in terms of deep symptom relief, comprehensive benefits in all subtypes, and markedly extended survival.
Express News | Sunvozertinib's Global Pivotal Wu-Kong1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations
Digger Pharmaceuticals (688192.SH): Schwarzer's first globally registered clinical study reached a major research endpoint and gave an oral report at the 2024 American Society of Clinical Oncology (ASCO) Conference
Ge Longhui, June 2, 丨 Di Zhe Pharmaceutical (688192.SH) issued an announcement. Recently, at the 2024 American Society of Clinical Oncology (ASCO) conference, Dizhe (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) first released the self-developed novel Class I lung cancer target drug Schwozhe (generic name: sulvortinib tablets) targeting the epidermal growth factor receptor (EGFR) No. 20 exon insertion mutation (exon20ins) of non-small cell lung cancer (NSCLC) for the first time in the form of an oral report Research “Goku 1B” (WU-KON
Dizal Reveals New Findings From Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
2024 ASCO | Dizhe Pharmaceutical's latest exploratory biomarker analysis adds new data to Schwarzer's treatment of EGFR exon20ins mutant non-small cell lung cancer
Baseline plasma circulating tumor DNA (ctDNA) tests positive and negative epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutations were observed to benefit after receiving Schwarzhe treatment. Schwarzhe directly acts on the EGFR signaling pathway and can effectively remove the EGFR exon20ins mutation in plasma ctDNA. Schwarzell's drug resistance mechanism shows EGFR-dependent and EGFR-independent pathways. Goliximinib (JAK1 inhibitor) combined chemotherapy is a potential solution in Shanghai 2024 May 24
Digger Pharmaceuticals (688192.SH): Schwarzer's latest research results were selected for the 2024 American Society of Clinical Oncology Conference Report
Glonghui, May 24, 丨 Dizhe Pharmaceutical (688192.SH) announced that at the American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago from May 31 to June 4, 2024, the company will announce the two latest research results of its self-developed novel Class I lung cancer target drug Schwarzhe (generic name: sulvortinib tablets) targeting epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutant advanced non-small cell lung cancer (NSCLC). Among them is Schwarzer? Global Note on Treated EGFrexon20InS Mutant NSCLC
Downgrade: Here's How Analysts See Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Performing In The Near Term
Dizhe Pharmaceutical (688192.SH): Chairman and others completed an increase in holdings of 6.59 million yuan
Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) announced that as of May 8, 2024, Dr. Zhang Xiaolin, Chairman and CEO of the company, Mr. Lu Hongbin, Secretary of the Board of Directors and Chief Financial Officer, and Ms. Wu Qingyi, Deputy General Manager and Chief Commercial Officer, have increased their holdings by 1991.88 million shares, accounting for 0.0479% of the company's total share capital, with a total increase of 6.597.42 million yuan. The plan to increase holdings has been completed.
These 4 Measures Indicate That Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Is Using Debt Reasonably Well
Dizhe Pharmaceutical (688192.SH) announced first-quarter results with a net loss of 224 million yuan
Dizhe Pharmaceutical (688192.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved an operating income of 8...
Dizhe Pharmaceutical (688192.SH) announced its 2023 annual results with a net loss of 1.08 billion yuan
Dizhe Pharmaceutical (688192.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 9...
2024 CSCO guide major update! Schwarzhe was included in the Level I recommendation, and goliximitinib was recommended for the first time, breaking through the bottleneck of treating difficult tumor targets
SHANGHAI, April 27, 2024/PRNewswire/ -- From April 26 to 27, 2024, the Chinese Society of Clinical Oncology (CSCO) guidelines conference was held in Jinan. In the 2024 CSCO diagnosis and treatment guidelines released at this conference, the two original innovative drugs independently developed by Dizhe Pharmaceutical (stock code: 688192.SH), and golisitinib, were both included in the guidelines as recommended drugs. Schwarzhe was recommended by the “CSCO Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer (2024 Edition)” at Level I, which targets experience in this guideline
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Digger Pharmaceuticals (688192.SH): Schwarzhe was recognized as a “breakthrough therapy” by the FDA
Dizhe Pharmaceutical (688192.SH) issued an announcement, and the company's product Suvorazhe (generic name: suvoritinib) was awarded by the United States...
Analysis
Price Target
No Data
